Filing Analysis
Pasithea Therapeutics Corp. has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share. The extension period expires on February 16, 2027.
🚩 Red Flags
- Ongoing non-compliance with Nasdaq minimum bid price requirement ($1.00).
- Potential for a reverse stock split to artificially inflate share price.
- Risk of delisting if compliance is not met by February 16, 2027.
📋 Key Facts
- The company was non-compliant with Nasdaq Listing Rule 5550(a)(2) due to the stock price falling below $1.00 for 30 consecutive business days.
- Nasdaq granted a 180-day extension to regain compliance, moving the deadline from August 19, 2026, to February 16, 2027.
- The company is considering a reverse stock split as a potential method to regain compliance.
- Failure to regain compliance by the deadline will result in a delisting notice and potential appeal to a Nasdaq hearings panel.
Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer and approved significant stock option grants for its executive team and board. The new CMO brings substantial experience from Genentech and Arcus Biosciences to lead the clinical development of PAS-004.
🚩 Red Flags
- Large-scale equity grants to existing management and directors (over 5.2 million shares total) following dilutive capital raises.
- The company's stock price is below $1.00 ($0.841), placing it at risk of Nasdaq minimum bid price non-compliance if it remains there.
📋 Key Facts
- Dr. Kartik Krishnan appointed Chief Medical Officer effective May 1, 2026, with a base salary of $500,000.
- Dr. Krishnan previously served as CEO of OncoNano Medicines and CMO of Arcus Biosciences, and was involved in the FDA approval of Cotellic™ at Genentech.
- The Board approved massive stock option grants: 1,756,069 shares to CEO Dr. Tiago Reis Marques and 1,129,323 shares each to CFO Daniel Schneiderman and CMO Dr. Krishnan.
- The exercise price for all new options is $0.841 per share, the closing price on May 1, 2026.
- The filing explicitly states these grants were made to 'reflect the ownership impact of certain recent capital raises,' suggesting significant prior dilution.
Pasithea Therapeutics Corp. (KTTA) received a Nasdaq non-compliance notice on February 20, 2026 for failing to maintain the $1.00 minimum bid price requirement under Rule 5550(a)(2), with its stock trading below $1.00 for 30 consecutive business days. The company has an initial 180-day cure period through August 19, 2026, with a possible second 180-day extension, but the filing explicitly references a potential reverse stock split as a compliance mechanism — a significant red flag for micro-cap shareholders.
🚩 Red Flags
- Nasdaq minimum bid price non-compliance — stock trading below $1.00 for 30+ consecutive business days indicates severe price deterioration
- Potential reverse stock split mentioned as a cure mechanism, which typically destroys shareholder value in micro-caps
- Emerging growth company with sub-dollar stock price suggests capital-raising difficulties and possible cash burn concerns
- Dual compliance periods (up to 360 days total) suggest Nasdaq expects difficulty in regaining compliance organically
- Warrants outstanding (KTTAW) add dilution overhang, making price recovery harder
📋 Key Facts
- Received Nasdaq non-compliance notice on February 20, 2026 for failure to meet $1.00 minimum bid price requirement (Rule 5550(a)(2))
- Company's common stock closing bid price was below $1.00 for 30 consecutive business days prior to the notice
- Initial 180-day compliance period granted, expiring August 19, 2026
- Company may be eligible for a second 180-day compliance period if it meets other listing requirements and notifies Nasdaq of intent to cure (e.g., via reverse stock split)
- No immediate delisting — compliance can be regained if bid price closes at or above $1.00 for 10 consecutive business days
- Company is an emerging growth company incorporated in Delaware, headquartered in Miami Beach, FL
- Listed on Nasdaq Capital Market; both common stock (KTTA) and warrants (KTTAW) are registered under Section 12(b)
- Par value of common stock is $0.0001 per share
- Filing signed by CEO Tiago Reis Marques
Pasithea Therapeutics Corp. held a Special Meeting of Stockholders on January 28, 2026, where shareholders approved two major structural changes: a massive increase in authorized common stock and an expansion of the company's 2023 Stock Incentive Plan.
🚩 Red Flags
- Significant increase in authorized share count (from 100M to 500M) creates substantial potential for future dilution via equity offerings or warrants.
- Expansion of the Stock Incentive Plan increases the pool of shares available for employee compensation, further contributing to dilution.
📋 Key Facts
- Stockholders approved increasing authorized Common Stock from 100,000,000 to 500,000,000 shares.
- The 2023 Stock Incentive Plan was amended to increase the share cap by 11,985,779 shares (totaling 14,000,000 shares).
- A quorum was established with 16,746,261 shares represented out of 23,091,062 outstanding.
- Proposal 1 (Authorized Shares) passed with 16,066,757 votes in favor.
- Proposal 2 (Incentive Plan) passed with 8,168,126 votes in favor.
Pasithea Therapeutics Corp. has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share. This follows a previous non-compliance notice issued on June 23, 2025.
🚩 Red Flags
- Historical delisting risk (the company was facing a deadline of December 22, 2025, to regain compliance).
📋 Key Facts
- The company was previously in violation of Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement.
- Nasdaq confirmed on December 12, 2025, that the common stock maintained a closing bid price at or above $1.00 for a sufficient number of consecutive business days.
- The compliance matter is now officially closed by Nasdaq.
Pasithea Therapeutics Corp. completed a best efforts public offering of common stock and pre-funded warrants, raising approximately $60 million in gross proceeds ($54.9 million net). The offering included significant participation from company insiders and the issuance of placement agent warrants.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 65 million pre-funded warrants that can be exercised at a nominal price ($0.001).
- Placement agent received significant compensation including 4,000,000 warrants.
- The offering structure (pre-funded warrants) is often used when companies face difficulty raising pure equity due to market conditions or existing ownership caps.
📋 Key Facts
- Gross proceeds: Approximately $60.0 million; Net proceeds (after fees/expenses): Approximately $54.9 million.
- Offering components: 14,846,665 shares of common stock at $0.75 per share and 65,153,335 pre-funded warrants at $0.749 per warrant.
- Pre-Funded Warrants have an exercise price of $0.001 per share and are immediately exercisable.
- Insiders (CEO, CFO, and certain directors) purchased 400,000 shares for approximately $300,000 at the offering price.
- H.C. Wainwright & Co., LLC acted as placement agent with a 7.0% cash fee.
- Placement Agent Warrants issued to Wainwright: 4,000,000 shares of common stock at an exercise price of $0.9375 per share.
- The offering closed on December 1, 2025.
Pasithea Therapeutics Corp. issued a series of positive clinical and strategic updates, including interim Phase 1 data for PAS-004 in solid tumors, favorable pharmacokinetic data for tablet formulations, and a ~$1 million grant from the ALS Association.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Interim Phase 1 data for PAS-004 showed a 71.4% Disease Control Rate (DCR) in BRAF-mutated tumors among evaluable patients.
- One melanoma patient achieved an unconfirmed partial response with a -31.9% tumor reduction following prior MEK + BRAF therapy.
- PAS-004 demonstrated linear pharmacokinetics and dose-proportionality across various cohorts.
- Tablet formulation showed 3-fold higher dose-normalized exposure compared to the capsule formulation.
- The ALS Association awarded a ~$1 million Hoffman ALS Clinical Trial Award grant to study PAS-004 in ALS patients.
Pasithea Therapeutics Corp. announced the activation of a new clinical trial site at the University of Alabama at Birmingham (UAB) for its Phase 1/1b study of PAS-004 in patients with neurofibromatosis type 1 (NF1). The company is also sponsoring an upcoming NF Caregivers Symposium.
📋 Key Facts
- Activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (UAB) for PAS-004 study.
- The Phase 1/1b study assesses safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in adults with NF1.
- Enrollment at the UAB site is expected to begin immediately as of November 4, 2025.
- Company will serve as Platinum Sponsor for the 2025 NF Caregivers Symposium on November 8, 2025.
Pasithea Therapeutics Corp. announced significant restructuring of executive and director compensation, primarily focused on conserving cash due to current financial constraints. The changes include salary adjustments for the CEO and CFO, a reduction in Board Chair compensation, and a drastic reduction in consulting fees for a Director.
🚩 Red Flags
- Explicit mention of 'current cash constraints' as the driver for compensation changes.
- Drastic reduction in consulting fees (from $100k/year to $4/year) indicates severe liquidity pressure.
- Significant shift toward equity-based compensation (options) over cash, which can lead to future dilution.
📋 Key Facts
- Effective retroactive to January 1, 2025: CEO Dr. Tiago Reis Marques's base salary increased to $533,000; target bonus decreased to 55%.
- Effective retroactive to January 1, 2025: CFO Daniel Schneiderman's base salary increased to $391,000; target bonus set at 40%.
- Board Chair annual cash compensation reduced from $100,000 to $35,000 effective October 1, 2025.
- Consulting agreement with Prof. Steinman reduced from $25,000 per quarter to $1.00 per quarter effective October 1, 2025.
- New stock option awards granted to executives and directors with an exercise price of $0.715 per share (based on Oct 24, 2025 closing price).
- Prof. Steinman awarded a one-time stock option for 200,000 shares in recognition of cash conservation efforts.
Pasithea Therapeutics Corp. announced clinical progress regarding its Phase 1/1b PAS-004 study for neurofibromatosis type 1 (NF1). The company has activated two new trial sites in South Korea and is proceeding with Cohort 2 dosing following a positive recommendation from the Safety Review Committee.
📋 Key Facts
- Activated two clinical trial sites in South Korea: Asan Medical Centre and Severance Hospital Yonsei University Health System.
- The first patient in South Korea has been dosed for the NF1 Trial.
- External Safety Review Committee recommended proceeding past Cohort 1 (4mg tablet) without modification.
- Company is currently enrolling patients in Cohort 2 (8mg tablet).
- Initial interim clinical data from the first two cohorts of the NF1 Trial is expected in Q1 2026.
Pasithea Therapeutics Corp. held its Annual Meeting of Stockholders on September 3, 2025, where shareholders approved several key measures including the election of directors and an amendment to the stock incentive plan. Most significantly, stockholders authorized the Board to implement a reverse stock split with a ratio ranging from 1:2 to 1:20.
🚩 Red Flags
- Approval of a reverse stock split (ranging from 1:2 to 1:20) often indicates an attempt to boost share price to maintain Nasdaq compliance or improve market perception.
- Significant increase in authorized shares under the Incentive Plan (from ~364k to over 2M, a nearly 5.5x increase), which may lead to significant shareholder dilution.
📋 Key Facts
- Annual Meeting held on September 3, 2025.
- Stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing authorized shares by 1,750,000 to a total of 2,014,221 shares.
- Stockholders approved a reverse stock split ratio ranging from 1-for-2 (1:2) to 1-for-20 (1:20), to be implemented at the Board's discretion prior to September 3, 2026.
- CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- Alfred Novak and Simon Dumesnil were elected to Class II director positions.
Pasithea Therapeutics Corp. has announced the date for its 2025 Annual Meeting of Stockholders, scheduled for September 3, 2025. The filing serves to establish deadlines for stockholder proposals and director nominations in compliance with SEC rules.
📋 Key Facts
- The 2025 Annual Meeting of Stockholders is set for September 3, 2025.
- Proxy materials are expected to be delivered/available on or about July 24, 2025.
- Deadline for Rule 14a-8 stockholder proposals: July 21, 2025.
- Deadline for notice of director nominees under universal proxy rules (Rule 14a-19): July 21, 2025.
Pasithea Therapeutics Corp. received a notice from Nasdaq stating it is in non-compliance with the $1.00 minimum bid price requirement. The company has 180 days to regain compliance, with a potential for an additional 180-day extension if they implement a reverse stock split.
🚩 Red Flags
- Delisting notice from Nasdaq
- Failure to maintain minimum bid price requirement ($1.00)
- Potential for an imminent reverse stock split to avoid delisting
📋 Key Facts
- Received written notice from Nasdaq on June 23, 2025.
- Non-compliance is due to the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- The deficiency was triggered by the stock closing below $1.00 for 30 consecutive business days prior to the notice.
- Initial compliance period expires on December 22, 2025.
- To regain compliance during a potential second 180-day window, the company may need to effect a reverse stock split.
Pasithea Therapeutics Corp. has increased the maximum aggregate offering price of its common stock under an existing At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC. This increase allows for the registration and potential sale of an additional $2,151,000 in shares.
🚩 Red Flags
- Continued reliance on ATM offerings suggests a need for immediate liquidity to fund operations.
- Potential dilution for existing shareholders as new shares are issued into the market.
📋 Key Facts
- Increased maximum aggregate offering price from $2,076,000 to $4,227,000 under the Sales Agreement dated November 26, 2024.
- The increase represents an additional $2,151,000 of Common Stock available for sale via the ATM program.
- Prior to this filing, the Company had already sold approximately $2,075,688 in shares under the original agreement.
- The offering is being conducted through H.C. Wainwright & Co., LLC.
Pasithea Therapeutics Corp. closed a best-efforts public offering of common stock and various warrants on May 7, 2025, raising approximately $6.3 million in gross proceeds. The offering included significant issuance of pre-funded warrants and multiple series of common warrants to investors.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 7 million warrants (Series C and D).
- Complexity of the capital structure involving pre-funded warrants, Series C, and Series D warrants.
- High placement agent fees (8% total cash fee plus reimbursement of significant legal/expense costs).
📋 Key Facts
- Closed a best-efforts public offering on May 7, 2025.
- Sold 3,094,284 shares of common stock at $1.40 per share.
- Issued 477,144 pre-funded warrants (exercisable at $0.001/share) and 7,142,856 total common warrants (Series C and D).
- Gross proceeds from the offering and warrant exercises totaled approximately $6.3 million.
- Net proceeds to the company are estimated at $4.3 million after fees and expenses.
- H.C. Wainwright & Co., LLC acted as placement agent, receiving a 7% cash fee and a 1% management fee.
- The company agreed to a 90-day standby on issuing new equity and a one-year restriction on Variable Rate Transactions.
Pasithea Therapeutics Corp. has dismissed its independent auditor, Marcum LLP, and appointed CBIZ CPAs P.C. for the fiscal year ending December 31, 2025. The filing notes that previous audits included explanatory paragraphs regarding substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language present in previous audit reports (FY2023 and FY2024).
- Auditor change occurring alongside existing going concern concerns.
- History of material weakness in internal controls over financial reporting (tax provision).
📋 Key Facts
- Dismissed Marcum LLP as independent accounting firm on April 23, 2025.
- Engaged CBIZ CPAs P.C. for the fiscal year ending December 31, 2025.
- Previous audits (FY2023 and FY2024) included explanatory paragraphs regarding 'substantial doubt about the Company’s ability to continue as a going concern'.
- A material weakness related to annual income tax provision review was identified in FY2023 and remediated by December 31, 2024.
- No disagreements on accounting principles or auditing scope were reported between the company and Marcum.
Pasithea Therapeutics Corp. entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC on November 26, 2024. This agreement allows the company to sell common stock from time to time through a prospectus supplement.
🚩 Red Flags
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can lead to significant shareholder dilution.
- The relatively small aggregate market value ($2.076M) suggests a need for incremental liquidity injections.
📋 Key Facts
- Entered into ATM Agreement with H.C. Wainwright & Co., LLC on November 26, 2024.
- The aggregate market value of shares eligible for sale is $2,076,000 (based on General Instruction I.B.6 of Form S-3).
- Sales Agent receives a cash commission equal to 3.0% of the gross sales price.
- Company will reimburse Sales Agent up to $100,000 for legal counsel fees and additional amounts for due diligence updates ($5,000 per session/report).
- The offering is conducted under an existing shelf registration statement on Form S-3 (File No. 333-271010) declared effective April 19, 2023.
Pasithea Therapeutics Corp. entered into a securities purchase agreement for a private placement of pre-funded warrants and Series A/B warrants to an institutional investor, netting approximately $4.5 million in proceeds. The deal includes significant warrant coverage and registration rights agreements.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 3.6 million total warrant-related shares.
- Pre-funded warrants with a near-zero exercise price ($0.001) create immediate dilutive pressure upon conversion.
- The company is subject to a 'no-issuance' period for common stock or equivalents for 90 days following the registration statement effectiveness, limiting future financing flexibility.
- High cost of capital: The placement agent receives significant cash fees and additional warrants based on exercise volume.
📋 Key Facts
- Private placement closed on September 30, 2024.
- Net proceeds of approximately $4.5 million for working capital and general corporate purposes.
- Issuance of Pre-Funded Warrants to purchase up to 1,219,513 shares at an exercise price of $0.001 per share.
- Issuance of Series A and B Warrants to purchase up to 1,219,513 shares each at an exercise price of $3.85 per share.
- H.C. Wainwright & Co., LLC acted as exclusive placement agent with a 7% cash fee and 1% management fee.
- Placement agent received warrants for up to 85,366 shares at $5.125 per share plus additional contingent warrants.
Pasithea Therapeutics Corp. issued a press release regarding positive preliminary clinical data from its Phase 1 trial of PAS-004 for the treatment of advanced cancer.
📋 Key Facts
- Reported date: September 26, 2024
- Clinical asset: PAS-004
- Trial phase: Phase 1 clinical trial
- Indication: Advanced cancer
- Data reported: Positive initial safety, tolerability, pharmacokinetic, and preliminary efficacy data
Pasithea Therapeutics Corp. held its 2024 Annual Meeting of Stockholders on June 26, 2024. The meeting resulted in the election of Dr. Emer Leahy to the Board of Directors and the ratification of Marcum LLP as the company's independent auditor for fiscal year 2024.
🚩 Red Flags
- Low quorum participation: Only ~35% of outstanding shares were represented at the meeting.
📋 Key Facts
- Annual Meeting held on June 26, 2024.
- Dr. Emer Leahy was elected to a Class I director position with a term expiring in 2027.
- Marcum LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Quorum was established by 369,617 shares representing approximately 35.4% of outstanding common stock (1,043,248 shares).
Pasithea Therapeutics Corp. has scheduled its 2024 Annual Meeting of Stockholders for June 26, 2024. The company established a record date of April 29, 2024, and set a deadline of May 24, 2024, for stockholder proposals.
📋 Key Facts
- Annual Meeting Date: June 26, 2024, at 9:00 a.m. ET via the Internet.
- Record Date: April 29, 2024.
- Stockholder Proposal Deadline: Close of business on May 24, 2024.
- Meeting Format: Virtual/Internet-based.
Pasithea Therapeutics Corp. has successfully regained compliance with Nasdaq's $1.00 minimum bid price requirement. The company maintained a closing bid price at or above $1.00 for the required consecutive business days, resolving the deficiency notice issued in 2023.
🚩 Red Flags
- Historical delisting risk (though this specific filing resolves the immediate threat).
📋 Key Facts
- The Company received a letter from Nasdaq on January 17, 2024, confirming compliance with the minimum bid price requirement.
- Compliance was achieved by maintaining a closing bid price at or above $1.00 per share for a sufficient number of consecutive business days.
- The deficiency matter is now considered closed by Nasdaq.
- Previous non-compliance notice was issued on January 19, 2023, with an extension deadline of January 15, 2024.
Pasithea Therapeutics Corp. announced the approval of significant corporate governance changes and a 1-for-20 reverse stock split during its reconvened annual meeting on December 29, 2023.
🚩 Red Flags
- Reverse stock split (1:20) implemented to maintain Nasdaq compliance or address low share price.
- Significant reduction in shareholder rights, including the elimination of written consent and imposition of supermajority requirements for bylaw changes.
- Board classification and 'for cause' removal provisions make it significantly harder for activist investors or shareholders to change management.
📋 Key Facts
- A 1-for-20 (1:20) reverse stock split was effective as of 12:01 a.m. on January 2, 2024.
- Stockholders approved amending the Certificate of Incorporation to classify the Board into three staggered classes with three-year terms; removal of directors now requires 'cause'.
- The ability for stockholders to act by written consent has been eliminated.
- Amending Bylaws now requires a supermajority vote of at least 66.7% of outstanding Common Stock.
- An exclusive forum provision was added, designating Delaware courts as the sole venue for legal actions.
- Officers are now exculpated from monetary liability in certain circumstances under Delaware law.